Find uplifting stories about heroes, innovations, and solutions
16 results for "sanofi"
A new documentary series reveals how pharmaceutical breakthroughs travel from laboratory discovery to millions of patients worldwide. Thousands of workers transform scientific hope into real medicines through cutting-edge technology and human dedication.
The FDA just approved teplizumab for children aged 8 and older with stage 3 type 1 diabetes, expanding treatment options for young patients. This marks an important step forward in managing a disease that affects over 300,000 American children.
Eight major pharmaceutical companies are investing $1.2 billion to help Mexico produce its own medications domestically. The initiative aims to lower drug costs and reduce the country's dependence on imported medicines.
A single-dose treatment for sleeping sickness just received European approval, replacing brutal treatments with three tablets. The breakthrough brings Africa within reach of eliminating a disease that killed tens of thousands just two decades ago.
Major global companies are partnering with Singapore startups to transform waste into valuable resources while slashing carbon emissions. From robots sorting electronic waste to medical plastics paving roads, these collaborations are proving sustainability drives profit and growth.
A renewable energy company is creating 90 new jobs across Ireland and the UK as demand for solar and battery storage solutions soars. The expansion comes as businesses rush to meet new sustainability requirements and cut their carbon footprints.
A new therapeutic vaccine targeting acne-causing bacteria has entered clinical trials in China, offering hope for millions who struggle with treatment-resistant breakouts. The protein-based shot marks a global shift toward immune-based solutions for the world's eighth most common skin condition.
A new flu vaccine using the same technology that powered COVID shots just proved more effective than traditional options in a 40,000-person study. The breakthrough could reshape how we protect ourselves from seasonal flu.
Sixteen major pharmaceutical companies agreed to cut prescription drug prices for Americans through a new discount platform called TrumpRx. Popular medications including weight-loss drugs, diabetes treatments, and asthma inhalers will now cost significantly less for millions of consumers.
Australia just approved the first new type 1 diabetes therapy since insulin was discovered over a century ago. The treatment can delay disease progression by an average of two years, giving families precious time before daily insulin begins.
A groundbreaking treatment just approved in England could transform life for nearly 30,000 people struggling to breathe with chronic lung disease. The twice-monthly injection is the first to tackle both symptoms and root causes of COPD.
A single-dose pill that cures sleeping sickness in one day just received approval, replacing treatments that once required 10 days or dangerous arsenic injections. After decades of African-led research, this breakthrough could help eliminate a disease that's killed millions.
A breakthrough eczema treatment matches leading medications but requires injections only twice a year instead of every two weeks. Apogee Therapeutics' study shows patients maintained clear, itch-free skin with dramatically fewer doctor visits.
Nearly 30,000 people in England with chronic lung disease will gain access to the first treatment that targets an underlying cause, not just symptoms. The twice-monthly injection cuts severe flare-ups by 30% and could save the NHS millions.
Two children at BC Children's Hospital became the first in Canada to receive a treatment that can delay type 1 diabetes by about two years. This marks a historic shift from just managing the disease to actually changing its course.
A groundbreaking injection just got approved for NHS use in England and Wales, offering fresh hope to 30,000 people struggling with severe COPD. This marks the first biologic therapy available for uncontrolled chronic lung disease after years of limited innovation.